Company Profile
Abnova (Taiwan) provides the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents.
The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations
MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. Additionally, it provides integrated solutions and services, including gene synthesis and cytogenetics.
Its portfolio also includes peptide services, protein expression, and conjugations, antibody production and scale up, assay development services, circulating tumor cell and DNA, germline genetic DNA, and FFPE tumor tissue DNA services. The company serves academic, research institutions, and pharmaceutical factories. Founded in 2002, Abnova (Taiwan) is headquartered in Taipei, Taiwan.